Expression of galectin-3 in gastric adenocarcinoma

被引:0
|
作者
Gomes, Thiago Simao [1 ]
Fujiyama Oshima, Celina Tizuko [1 ]
Forones, Nora Manoukian [2 ]
Lima, Flavio De Oliveira [1 ]
Ribeiro, Daniel Araki [3 ]
机构
[1] Univ Fed Sao Paulo, Dept Pathol, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Oncol Grp, Div Gastroenterol, Dept Med, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biosci, Sao Paulo, Brazil
关键词
Biomarker; galectin-3; gastric adenocarcinoma; immunoexpression; prognosis; CARBOHYDRATE BINDING PROTEIN-35; CYTOPLASMIC GALECTIN-3; CANCER; LECTIN; CELLS; PROGRESSION; CARCINOMA; FAMILY; MACROPHAGES; SEQUENCE;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Galectin-3 a member of the galectin family is an endogenous beta-galactoside binding lectin. It has been found to be associated with cell adhesion, recognition, proliferation, differentiation, immunomodulation, angiogenesis, apoptosis and can be a reliable marker for cancer aggressiveness. The aim of this study was to verify protein expression in gastric adenocarcinoma tissues and correlate the results with the clinical aspects in the study population. Methods: Galectin-3 expression was examined by immunohistochemistry in 57 samples of gastric adenocarcinomas tissues. Galectin-3 protein expression was observed in the cytoplasm and the nucleus of examined tissues. Results: Thirty one (54.4%) samples had strong or moderate staining and 26 (45.6%) tumours had negative or weak staining. The galectin-3 did not show association with the sex (p=0.347), age (p=0.999), Lauren's classification (p=0.731) and TNM stage (p=0.222). Regarding the TNM stage, 66.7 per cent of stage I tumours had strong or moderate staining; with tumours stage IV this percentage was 33.3 per cent. Interpretation & conclusion: Our results suggest that gal-3 is not a reliable biomarker for prognosis of the gastric adenocarcinoma by immunohistochemistry. Further studies need to be done on a large sample of tumour tissues in different clinical staging.
引用
收藏
页码:69 / 76
页数:8
相关论文
共 50 条
  • [21] Endogenous galectin-3 expression levels modulate immune responses in galectin-3 transgenic mice
    Chaudhari, Aparna D.
    Gude, Rajiv P.
    Kalraiya, Rajiv D.
    Chiplunkar, Shubhada V.
    MOLECULAR IMMUNOLOGY, 2015, 68 (02) : 300 - 311
  • [22] Serum Galectin-3 as a Potential Marker for Gastric Cancer
    Cheng, Daye
    Liang, Bin
    Li, Yunhui
    MEDICAL SCIENCE MONITOR, 2015, 21 : 755 - 760
  • [23] Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma
    VandenBrule, FA
    Buicu, C
    Berchuck, A
    Bast, RC
    Deprez, M
    Liu, FT
    Cooper, DNW
    Pieters, C
    Sobel, ME
    Castronovo, V
    HUMAN PATHOLOGY, 1996, 27 (11) : 1185 - 1191
  • [24] Hydrocortisone and dexamethasone affect galectin-3 expression
    Dabelic, S
    Flögel, M
    Dumic, J
    PERIODICUM BIOLOGORUM, 2005, 107 (02) : 175 - 181
  • [25] Differential expression of galectin-3 in pituitary tumors
    Riss, D
    Jin, L
    Qian, X
    Bayliss, J
    Scheithauer, BW
    Young, WF
    Vidal, S
    Kovacs, K
    Raz, A
    Lloyd, RV
    CANCER RESEARCH, 2003, 63 (09) : 2251 - 2255
  • [26] Decreased galectin-3 expression in prostate cancer
    Pacis, RA
    Pilat, MJ
    Pienta, KJ
    Wojno, K
    Raz, A
    Hogan, V
    Cooper, CR
    PROSTATE, 2000, 44 (02): : 118 - 123
  • [27] Immunohistochemical detection of galectin-3 in canine gastric carcinomas
    Woo, HJ
    Joo, HG
    Song, SW
    Sohn, YS
    Chae, C
    JOURNAL OF COMPARATIVE PATHOLOGY, 2001, 124 (2-3) : 216 - 218
  • [28] Curcumin -: A potent inhibitor of galectin-3 expression
    Dumic, J
    Dabelic, S
    Flögel, M
    FOOD TECHNOLOGY AND BIOTECHNOLOGY, 2002, 40 (04) : 281 - 287
  • [29] EXPRESSION OF GALECTIN-3 IN PRIMARY AND METASTATIC MELANOMAS
    Russo, J.
    Allan, R.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2009, 36 (01) : 159 - 159
  • [30] Expression of antigen tf and galectin-3 in fibroadenoma
    Gallegos I.B.
    Pérez-Campos E.
    Martinez M.
    Mayoral M.A.
    Pérez L.
    Aguilar S.
    Zenteno E.
    Pina M.D.S.
    Hernández P.
    BMC Research Notes, 5 (1)